文献速递糖尿病

血浆岩藻糖基化聚糖与C反应蛋白作为青年起病非自身免疫性糖尿病HNF1A-MODY生物标志物

Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes.
PubMed 文献 · Diabetes Care · 2018-11-19

在989例45岁前起病、内源性胰岛素持续分泌且无胰腺自身免疫的糖尿病患者中,分析血浆N-聚糖谱、检测hs-CRP并测序HNF1A,以评估其区分致病性HNF1A等位基因携带者的能力。共发现29人携带25种罕见HNF1A等位基因(3种为新发现),其中12种(见于16名先证者)判为致病性。岩藻糖基化N-聚糖与hs-CRP均可区分致病性HNF1A等位基因携带者与无罕见HNF1A等位基因者。

要点

  • 聚糖GP30的AUC为0.90,灵敏度88%、特异度80%,cutoff 0.70%。
  • hs-CRP的AUC为0.83,灵敏度88%、特异度69%,cutoff 0.81 mg/L。
  • 约半数罕见HNF1A序列变异并不导致MODY,需警惕误判。

核心结论

  • 血浆N-聚糖谱与hs-CRP可单独或作为现有路径的辅助工具,识别携带致病性HNF1A等位基因的高风险个体。

研究设计与样本

  • 在989例45岁前诊断糖尿病、内源性胰岛素持续分泌且无胰腺自身免疫的个体中,分析血浆N-聚糖谱、检测hs-CRP并对HNF1A测序。
  • 对罕见HNF1A变异进行系统评估。

主要发现

  • 共识别29人携带25种罕见HNF1A等位基因,其中3种为新发现,12种(见于16名先证者)判为致病性。
  • 岩藻糖基化N-聚糖与hs-CRP均能区分致病性HNF1A等位基因携带者与无罕见HNF1A等位基因者。
  • GP30的AUC为0.90(灵敏度88%、特异度80%,cutoff 0.70%),hs-CRP的AUC为0.83(灵敏度88%、特异度69%,cutoff 0.81 mg/L)。

关键数值与推荐

  • GP30判别致病性HNF1A等位基因的AUC 0.90,灵敏度88%、特异度80%,cutoff 0.70%。
  • hs-CRP判别致病性HNF1A等位基因的AUC 0.83,灵敏度88%、特异度69%,cutoff 0.81 mg/L。
  • 25种罕见HNF1A等位基因中仅12种(16名先证者)判为致病性,提示约半数罕见变异不致病。

临床怎么用

  • 对青年起病非自身免疫性糖尿病且疑诊MODY者,可考虑用N-聚糖谱或hs-CRP辅助筛选基因检测对象。
  • 明确HNF1A-MODY后可将磺脲类作为一线治疗,减少误诊带来的治疗机会损失。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Maturity-onset diabetes of the young (MODY) due to variants in HNF1A is the most common type of monogenic diabetes. Frequent misdiagnosis results in missed opportunity to use sulfonylureas as first-line treatment. A nongenetic biomarker could improve selection of subjects for genetic testing and increase diagnosis rates. We previously reported that plasma levels of antennary fucosylated N-glycans and high-sensitivity C-reactive protein (hs-CRP) are reduced in individuals with HNF1A-MODY. In this study, we examined the potential use of N-glycans and hs-CRP in discriminating individuals with damaging HNF1A alleles from those without HNF1A variants in an unselected population of young adults with nonautoimmune diabetes. RESEARCH DESIGN AND METHODS: We analyzed the plasma N-glycan profile, measured hs-CRP, and sequenced HNF1A in 989 individuals with diabetes diagnosed when younger than age 45, persistent endogenous insulin production, and absence of pancreatic autoimmunity. Systematic assessment of rare HNF1A variants was performed. RESULTS: We identified 29 individuals harboring 25 rare HNF1A alleles, of which 3 were novel, and 12 (in 16 probands) were considered pathogenic. Antennary fucosylated N-glycans and hs-CRP were able to differentiate subjects with damaging HNF1A alleles from those without rare HNF1A alleles. Glycan GP30 had a receiver operating characteristic curve area under the curve (AUC) of 0.90 (88% sensitivity, 80% specificity, cutoff 0.70%), whereas hs-CRP had an AUC of 0.83 (88% sensitivity, 69% specificity, cutoff 0.81 mg/L). CONCLUSIONS: Half of rare HNF1A sequence variants do not cause MODY. N-glycan profile and hs-CRP could both be used as tools, alone or as adjuncts to existing pathways, for identifying individuals at high risk of carrying a damaging HNF1A allele.

来源:Diabetes Care,查看原文。版权归原作者所有。

引用

  1. Juszczak A, Pavić T, Vučković F, et al. Plasma Fucosylated Glycans and C-Reactive Protein as Biomarkers of HNF1A-MODY in Young Adult-Onset Nonautoimmune Diabetes. Diabetes Care. 2018. PMID: 30455330. doi:10.2337/dc18-0422

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。